Lee’s Pharmaceutical posts flat profit on higher costs, trims final dividend

The latest announcement is out from Lee’s Pharmaceutical Holdings Limited ( (HK:0950) ).

Lee’s Pharmaceutical Holdings Limited reported a modest 2.6% increase in revenue to HK$1.44 billion for the year ended 31 December 2025, while gross profit slipped 3.2% to HK$729.6 million. Profit attributable to shareholders edged down 1.2% to HK$91.9 million, with basic and diluted earnings per share easing to 15.61 HK cents.

Operating performance softened as higher cost of sales and increased research and development spending compressed margins and reduced profit from operations to HK$86.0 million. The board recommended a slightly lower final dividend of HK2.3 cents per share versus the prior year, signaling a cautious capital return stance amid stable but pressured profitability and ongoing investment in future growth.

The most recent analyst rating on (HK:0950) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Lee’s Pharmaceutical Holdings Limited stock, see the HK:0950 Stock Forecast page.

More about Lee’s Pharmaceutical Holdings Limited

Lee’s Pharmaceutical Holdings Limited is a Hong Kong-listed pharmaceutical group focused on the research, development, manufacturing and sales of prescription drugs. The company operates in the healthcare sector, generating revenue primarily from pharmaceutical products and related services across its core therapeutic franchises.

Average Trading Volume: 801,960

Technical Sentiment Signal: Sell

Current Market Cap: HK$777.3M

For an in-depth examination of 0950 stock, go to TipRanks’ Overview page.